Molecular genetic markers of predisposition to thrombosis in adolescents with essential hypertension
- Authors: Dolgikh VV1, Bol'shakova SE1, Kolesnikova LI1, Mikhalevich IM1
-
Affiliations:
- ФГБУ "Научный центр проблем здоровья семьи и репродукции человека" СО РАМН, Иркутск
- Issue: Vol 86, No 9 (2014)
- Pages: 45-48
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31552
- ID: 31552
Cite item
Full Text
Abstract
AIM. To estimate the spread and distribution of genotypes and alleles of thrombosis predisposition gene polymorphisms in adolescents with essential hypertension (EH). MATERIALS AND METHODS. One hundred and thirty-seven 14- to 17-year-old adolescents were examined. There were 3 examined groups: 1) 37 EH patients with prothrombotic changes (PTC); 2) 60 EH patients without PTC; 3) 40 healthy adolescents. Prothrombin time, activated partial thromboplastin time, and the levels of fibrinogen and soluble fibrin monomer complexes were determined. The adolescents were assigned to a PTC group if they had changes by one or several above indicators. Polymerase chain reaction assay was used to type coagulation factor II (FII) and factor V (FV), plasminogen activator inhibitor type 1 (PAI-1), 5,10-methylenetetrahydrofolate reductase (MTHFR), and methionine syntase reductase (MTRR) gene polymorphisms. Group differences were determined by qualitative signs, by using the χ2 test and Yates' correction for continuity and Fisher's exact test if one of the groups had at least 5 individuals. All differences were considered statistically significant at p<0.05. RESULTS. FV R506Q, FII G20210A, PAI1 -675 4G/5G, MTHFR A1298C, and MTRR A66G polymorphisms have not been found to affect the hemostatic system in adolescents with EH. MTHFR С677Т may act as a risk factor of PTC in adolescents with EH, by increasing the risk of thrombotic events at an old age. CONCLUSION. It is recommended that the determination of molecular genetic markers for predisposition to thrombosis be actively used in adolescents with EA to form a risk group for thrombotic events and to implement preventive measures.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V V Dolgikh
ФГБУ "Научный центр проблем здоровья семьи и репродукции человека" СО РАМН, Иркутск
S E Bol'shakova
ФГБУ "Научный центр проблем здоровья семьи и репродукции человека" СО РАМН, Иркутск
Email: sebol@bk.ru
L I Kolesnikova
ФГБУ "Научный центр проблем здоровья семьи и репродукции человека" СО РАМН, Иркутск
I M Mikhalevich
ФГБУ "Научный центр проблем здоровья семьи и репродукции человека" СО РАМН, Иркутск
References
- Житникова Л.М. Ацетилсалициловая кислота в профилактике и лечении сердечно-сосудистых заболеваний: клинические рекомендации для практикующих врачей. Рус мед журн 2012; 14: 708-714.
- Леонтьева И.В. Проблема артериальной гипертензии у детей и подростков. Рос вестн перинатол и педиатрии 2006; 5: 7-18.
- Верещагин Н.В., Суслина З.А., Максимова М.Ю. Артериальная гипертония и цереброваскулярная патология: современный взгляд на проблему. Кардиология 2004; 3: 4-8.
- Солнцева О.А., Подчерняева Н.С., Рабиева Г.М. и др. Антифосфолипидные антитела и генетические мутации в системе гемостаза у детей с системной красной волчанкой и ювенильным дерматомиозитом. Рос педиатр журн 2006; 5: 23-29.
- Arsov T., Miladinova D., Spiroski M. Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels. Croat Med J 2006; 47: 433-439.
- Козловская Н.Л. Тромбофилические состояния. Клин фармакол и тер 2003; 1: 74-80.
- Naran N.H., Chetty N., Crowther N.J. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atheroscler 2008; 196 (1): 155-163.
- Страмбовская Н.Н., Витковский Ю.А., Сизикова О.Н., Паламова Р.Ц. Первичные тромбофилии у больных ишемическим инсультом в Республике Бурятия. Забайкальский мед вестн 2010; 1: 47-51.
- Singh P.R., Lele S.S. Folate gene polymorphisms MTR A2756G, MTRR A66G, and BHMT G742A and risk for coronary artery disease: a meta-analysis. Genetic Testing and Molecular Biomarkers 2012; 16 (6): 471-475.
- Gaughan D.J., Kluijtmans L.A., Barbaux S. et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atheroscler 2001; 157 (2): 451-456.
- Scazzone C., Acuto S., Guglielmini E. et al. Methionine synthase reductase (MTRR) A66G polymorphism is not related to plasma homocysteine concentration and the risk for vascular disease. Exp Mol Pathol 2009; 86 (2): 131-133.
![](/img/style/loading.gif)